| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
|
Medicine details |
|
| Medicine name | bevacizumab (Avastin®) |
| Formulation | 25 mg/ml concentrate for solution for infusion |
| Reference number | 409 |
| Indication | In combination with capecitabine for first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab in combination with capecitabine |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/07/2011 |
| NICE guidance | |